- Palestinian billionaire Masri released by Saudis, to leave country soo
- U.S., Russian, Japanese crew blasts off for space station
- NY Times: Pentagon study of UFOs revealed
- Tens of thousands of Indonesians rally over Trump's Jerusalem stance
- Second prototype of China's C919 jet conducts test flight: state TV
- North Korea threat on agenda when South Korean foreign minister visits
- Pentagon study of UFOs revealed
- Australia arrests man accused of trying to sell missile parts for Nort
- How Australia's PM went swimming 50 years ago and vanished forever
- Hundreds come down with stomach illness during Royal Caribbean cruise
- Australian police accuse man of acting as North Korean economic agent
- Hoping to extend maritime reach, China lavishes aid on Pakistan town
- Mudslide in southern Chile kills five, at least 15 missing
- Honduran helicopter crash kills six, including president's sister
- Brazil's Workers Party formalizes support for ex-president Lula
- Foreign minister warns UK cannot become 'vassal state' of EU
- More than half of Britons now want to stay in EU - poll
- An update on winners and losers on the U.S. tax scorecard
- Uber accused of espionage, hacking and bribery in bombshell letter
- Christian Bale and more to salute CNN Heroes
FDA proposes drug development guidance for rare pediatric diseases
(Reuters) - The U.S. Food and Drug Administration issued a draft guidance on Wednesday to simplify the procedure of developing drugs for rare pediatric disorders, such as Gaucher’s disease, by eliminating the need for certain trials and minimizing patient enrollment.
The health regulator said the new approach reduces the number of patients on placebo by allowing companies to collaborate and test multiple drug products in the same clinical trial. bit.ly/2iwQt3i
The FDA said the draft guidance was developed in collaboration with the European Medicines Agency, using Gaucher’s as a disease model. It added that the proposal could be extended to other rare pediatric disorders.
Gaucher’s disease is a genetic disorder, which is caused by a deficiency of an enzyme required to break down certain fats, leading to enlarged liver and spleen.
The guidance is available for comment for about two months, after which the FDA will release its final determinations.
Reporting by Divya Grover in Bengaluru; Editing by Anil D'Silva
Our Standards:The Thomson Reuters Trust Principles.